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Abstract
 
Vav is a hematopoietic cell–specific guanine nucleotide exchange factor (GEF) whose activa-
tion is mediated by receptor engagement. The relationship of Vav localization to its function is
presently unclear. We found that Vav redistributes to the plasma membrane in response to Fc
 
e
 
receptor I (Fc
 
e
 
RI) engagement. The redistribution of Vav was mediated by its Src homology 2
(SH2) domain and required Syk activity. The Fc
 
e
 
RI and Vav were found to colocalize and
were recruited to glycosphingolipid-enriched microdomains (GEMs). The scaffold protein, linker
for activation of T cells (LAT), and Rac1 (a target of Vav activity) were constitutively present
in GEMs. Expression of an SH2 domain–containing COOH-terminal fragment of Vav inhib-
ited Vav phosphorylation and movement to the GEMs but had no effect on the tyrosine phos-
phorylation of the adaptor protein, SLP-76 (SH2 domain–containing leukocyte protein of 76
kD), and LAT. However, assembly of the multiprotein complex containing these proteins was
inhibited. In addition, Fc
 
e
 
RI-dependent activation of c-Jun NH
 
2
 
-terminal kinase 1 (JNK1)
was also inhibited. Thus, Vav localization to the plasma membrane is mediated by its SH2 do-
main and may serve to regulate downstream effectors like JNK1.
Key words: Vav • Fc
 
e
 
 receptor I • mast cell • glycosphingolipid-enriched microdomains • 
plasma membrane
 
Introduction
 
Understanding how receptors communicate with downstream
effectors poses a significant challenge in biology. Recent stud-
ies have begun to elucidate some of the workings, suggesting
that receptor-induced formation of macromolecular signaling
complexes, mediated by molecular scaffolds and adaptors
(1, 2), can link receptors to multiple signaling pathways.
However, where and how receptors engage these macro-
molecular complexes are still unresolved questions. The rec-
ognition that plasma membrane proteins and lipids can dif-
ferentially partition, forming discrete microdomains that are
enriched in particular types of proteins and lipids, has
prompted investigative efforts to determine if such domains
are critical components of receptor-mediated cellular signaling
(3–5). Glycosphingolipid-enriched microdomains (GEMs)
 
1
 
constitute one such membrane domain that concentrates
sphingolipids, cholesterol, glycophosphatidylinositol-linked
proteins, and numerous signaling molecules (4, 5). The con-
centration of diverse signaling molecules in these domains
suggests their importance in multiple signaling pathways.
Recently, Ag receptors (including Fc
 
e
 
RI) and costimu-
latory molecules have been shown to be constitutively
present or to partition to these domains upon their engage-
ment (6–8). Furthermore, recent work suggests that Vav
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Abbreviations used in this paper:
 
 CH, calponin homology; DH, Dbl ho-
mology; DNP, dinitrophenyl; GEF, guanine nucleotide exchange factor;
GEM, glycosphingolipid-enriched microdomain; GFP, green fluorescent
protein; HSA, human serum albumin; ITAM, immunoreceptor tyrosine-
based activation motif; JNK, c-Jun NH
 
2
 
-terminal kinase; LAT, linker for
activation of T cells; PH, pleckstrin homology; SH, Src homology; SFV,
Semliki Forest virus; SLP-76, SH2 domain–containing leukocyte protein
of 76 kD; TCA, trichloroacetic acid. 
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can be found complexed with linker for activation of T
cells (LAT), a scaffolding protein that partially partitions to
GEMs (9). Thus, GEMs are reasonable candidates as sites
for receptor–downstream effector coupling. In a prior study,
we found that Fc
 
e
 
RI could be coimmunoprecipitated with
the hematopoietic cell–specific protein, Vav, after receptor
aggregation (10). Because Fc
 
e
 
RI engagement results in the
movement of a considerable fraction of these receptors into
GEMs (6), perhaps GEMs might be sites of interaction be-
tween Fc
 
e
 
RI and Vav and thus Vav localization to GEMs a
required step for its function.
Tyrosine phosphorylation of Vav is important for its
GDP/GTP exchange activity that activates Rho family GTP-
ases like Rac1, which function(s) in the regulation of cellu-
lar architechture (11, 12). The guanine nucleotide exchange
factor (GEF) activity of Vav is encoded by the Dbl homol-
ogy (DH) domain, whose function has also been demon-
strated to contribute to c-Jun NH
 
2
 
-terminal kinase (JNK)
activation (11, 13). In addition to tyrosine phosphorylation,
products of phosphatidylinositol 3-kinase activation can
also contribute to the activation of Vav by binding to the
Vav pleckstrin homology (PH) domain, thus increasing its
activity (14). Among other structural domains of Vav are
two Src homology 3 (SH3) domains and an SH2 domain
(15) that can interact with a diverse array of proteins (15,
16) and thus contribute to Vav function. For example, the
Vav SH2 domain interacts with tyrosine kinases Syk and
ZAP-70 (17, 18) and adaptor molecules such as SH2 do-
main–containing leukocyte protein of 76 kD (SLP-76 [19])
and Cbl (20). Another adaptor molecule, Grb2, binds to
the NH
 
2
 
-terminal SH3 domain of Vav (21, 22). In addi-
tion, the Vav COOH-terminal SH3 domain binds the het-
erogeneous ribonuclear proteins (hnRNPs) K and C (23,
24), the nuclear protein Ku-70 (25), and the cytoskeletal
protein zyxin (26). Given the diversity of proteins with
which Vav can interact, enormous potential exists for the
modulation of its localization in response to cellular stimuli.
To investigate the localization of Vav and its functional
consequences, we tagged Vav with green fluorescent protein
(GFP) and followed its distribution in the RBL-2H3 mast
cell line before and after Fc
 
e
 
RI engagement. Phosphoryla-
tion of the immunoreceptor tyrosine-based activation motifs
(ITAMs [27]) of the Fc
 
e
 
RI by Lyn, after Fc
 
e
 
RI engagement,
results in the recruitment and activation of Syk by its interac-
tion with Fc
 
e
 
RI
 
g
 
 ITAM (28). Because Vav phosphorylation
is downstream of Syk activation (29, 30), we also investi-
gated the importance of Syk to Vav localization. Further-
more, as a measure of whether the intracellular localization
of Vav is important to its function, we assessed the activation
of JNK1, as Fc
 
e
 
RI-dependent JNK1 activation is mediated
by Vav (31). Our findings show that phosphorylation and re-
cruitment of Vav to the plasma membrane is an important
step in Vav function in mast cells.
 
Materials and Methods
 
Antibodies, Reagents, and Cell Cultures.
 
Mouse mAbs to Vav,
Rac1, LAT, phosphotyrosine (4G10), Grb2, SLP-76, and GFP
were purchased from Upstate Biotechnology, Transduction Lab-
oratories, and Clontech. A rabbit polyclonal antibody to LAT
was a gift of Lawrence Samelson (National Cancer Institute, Na-
tional Institutes of Health, Bethesda, MD). A rabbit polyclonal an-
tibody to Vav and a goat polyclonal antibody to JNK1 were from
Santa Cruz Biotechnology. Fluorescently labeled secondary anti-
bodies (Cy-5 or fluorescein conjugated) were purchased from
Jackson ImmunoResearch Labs. Mouse mAb to Fc
 
e
 
RI 
 
b
 
 chain
has been described (32), and a mouse monoclonal to Syk was a
gift from Petr Draber (Institute of Molecular Genetics, Prague,
Czech Republic). Anti-dinitrophenyl (DNP) specific murine IgE
was purified as described previously (33). DNP-human serum al-
bumin (HSA) was from Sigma Chemical Co. Mounting medium
(PermaFluor
 
®
 
 aqueous mounting medium) was from Immunon.
Enzymes used in this study were purchased from Life Technolo-
gies, Inc., and New England Biolabs. Piceatannol was purchased
from Calbiochem. The rat basophilic leukemia cell line (RBL-
2H3), RBL-2H3 TB1A2 (Syk
 
2
 
), RBL-2H3 3A1 (Syk
 
1
 
), and
RBL-2H3 3BA12 (kinase-dead Syk
 
1
 
) were cultured as described
previously (30). Baby hamster kidney (BHK) cells were cultured
as described by the American Type Culture Collection.
 
DNA Constructs, Recombinant Semliki Forest Virus, and Infec-
tion.
 
The Semliki Forest virus (SFV) expression system, pSFV1 and
helper pSFV2, was purchased from Life Technologies, Inc. All Vav
constructs were generated from the previously described rat Vav
(13). The pSFV1-GFP expression vector and Vav-GFP were gener-
ated as described (34). Vav (R694K) was PCR amplified from plas-
mid SR
 
a
 
Vav and cloned into pSFV1-GFP to generate the pSFV1-
VavSH2(R694K)-GFP as stated above. The calponin homology
(CH) domain–deleted, DH domain–deleted, PH domain–deleted,
and SH2 domain–deleted Vav constructs were generated from
pZeoSV-Vav plasmid by overlapping extension PCR with primers
to selectively delete the CH domain (from M1 to I126), DH do-
main (from K194 to I405), PH domain (from R402 to N505), and
SH2 domain (from W669 to L758). The COOH-terminal region
of Vav encoding the SH3-SH2-SH3 domains (Vav-C), starting at
amino acid I567 to C845, was also PCR amplified. Vav-C encod-
ing the R694K mutation was also PCR amplified from SR
 
a
 
Vav.
Full-length rat Syk was PCR amplified from plasmid SR
 
a
 
Syk.
PCR reactions used the proof-reading Pfu DNA polymerase (Strat-
agene). Fidelity was confirmed by direct sequencing.
Recombinant SFV generation and infection of RBL-2H3 cells
with the recombinant viruses were as described (34). Infectivity
of cells with Vav ranged from 75 to 90%.
 
Confocal Microscopy.
 
RBL-2H3 cells were grown on acid-
washed no. 1 coverslips in a 24-well plate as a subconfluent
monolayer culture for 16 h. After infection, cells were incubated
for an additional 4–6 h and sensitized with DNP-specific IgE
(34). Stimulation with varying concentrations of DNP-HSA was
for 3 min or as indicated. Coverslips were washed with PBS and
fixed with 3% paraformaldehyde in PBS. Fixed cells were either
directly analyzed or permeabilized with 0.5% Triton X-100 for 5
min at room temperature for immunostaining with primary anti-
bodies to Fc
 
e
 
RI 
 
b
 
 chain, Grb2, LAT, Rac1, or Syk followed by
a fluorescent secondary antibody (Cy-5–labeled goat anti–mouse
or anti–rabbit). Coverslips were air dried and mounted on glass
slides using PermaFluor
 
®
 
 aqueous mounting medium. Slides
were examined on a Zeiss LSM 410 confocal microscope using a
63
 
3
 
 Plan Apochromat objective (N.A. 1.4). GFP fluorescence
was visualized with 488-nm krypton/argon laser excitation and a
515–540-nm band pass emission filter. Cy-5 fluorescence was si-
multaneously viewed using 633-nm helium/neon excitation and
a 670–810-nm band pass emission filter. Brightness and contrast 
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settings for acquired images were adjusted to maximize dynamic
range and prevent detector saturation.
 
Isolation of GEMs, Immunoprecipitations, Western Blots, and In-
Gel Kinase Assays.
 
GEMs were isolated from transfected 
 
125
 
I-
IgE–labeled RBL-2H3 cells as described previously (35), except
that 0.1% Triton X-100 was used for cell solubilization. Fractions
were collected, and aliquots were counted for 
 
125
 
I-IgE distribu-
tion, then diluted 1:1 with lysis buffer (35) and subjected sequen-
tially to Vav, LAT, or Fc
 
e
 
RI immunoprecipitation or to precipita-
tion of all proteins with 20% trichloroacetic acid (TCA). For
immunoprecipitations, lysis buffer (which for solubilization of
GEMs included 0.5% 
 
b
 
-octyl glucoside) was added for 30 min
at 4
 
8
 
C. Lysates were incubated with protein A or protein G
Sepharose–bound antibodies to SLP-76, Vav, JNK1, Syk, Grb2, or
LAT overnight at 4
 
8
 
C as indicated. SDS-solubilized proteins were
resolved by SDS-PAGE, transferred to nitrocellulose, and probed
with 4G10 antibody. For TCA precipitates, recovered pellets were
washed once in ice-cold acetone, dried, and resuspended in 50 
 
m
 
l
of 1% SDS in 50 mM Tricine and 50 
 
m
 
l of twofold-concentrated
SDS sample buffer. Proteins were resolved and probed with anti-
bodies to Grb2, LAT, Lyn, paxillin, Rac1, SLP-76, Syk, and Vav
as indicated. In-gel kinase assays for JNK1 activation were done as
described (36). In brief, transfected cells were lysed as described
(34), and soluble lysates were incubated with goat anti-JNK1. Im-
munoprecipitates were resolved by SDS-PAGE gels containing
glutathione 
 
S
 
-transferase (GST)-ATF2 (300 
 
m
 
g/ml) as the substrate
for JNK1. The resolved proteins in the gel were denatured, and the
kinase reaction was carried out in kinase buffer (36).
 
Results
 
Vav Redistributes to the Plasma Membrane after Fc
 
e
 
RI En-
gagement.
 
RBL-2H3 cells expressing either GFP or Vav-
GFP were analyzed for the distribution of Vav. As shown
in Fig. 1 A, GFP was evenly distributed throughout the cell
and was included in the nucleus. No apparent association
of GFP with the plasma membrane was evident (Fig. 1 A).
In contrast, the addition of Vav to GFP caused a dramatic
change in the distribution of GFP, with little inclusion of
Vav-GFP in the nucleus. This suggested that Vav is primar-
ily localized to the cytosol and sequesters the fused GFP in
the cytosol. To verify that the addition of GFP to Vav did
not affect its localization, we determined the distribution of
endogenous Vav by immunofluorescence and found it to be
essentially identical (Fig. 1 A). A consistently higher back-
ground was found for the immunofluorescence staining with
antibody to Vav, and thus we focused on Vav-GFP redis-
tribution.
Fc
 
e
 
RI engagement resulted in the redistribution of a sig-
nificant fraction of Vav to the plasma membrane as a sub-
membranous aggregate at the indicated Ag concentrations
(Fig. 1 B). In contrast, no change in the distribution of
GFP was observed in response to Fc
 
e
 
RI engagement, al-
though the cells treated with 300 ng Ag showed increased
spreading or flattening (Fig. 1 B). Two distinct features of
Vav overexpression and its relationship to Fc
 
e
 
RI engage-
ment were observed. First, Vav overexpression resulted in
the spreading or flattening of the cells (Fig. 1 B), and this
was further enhanced by Fc
 
e
 
RI engagement. Second, the
redistribution of Vav was not uniform and seemed to be
most prominent at cell–cell contacts where one might ex-
pect larger aggregates of Fc
 
e
 
RI to form, provided that re-
ceptors on contacting cells bound the same Ag (Fig. 1 B).
In kinetic experiments, Vav moved to the plasma mem-
brane within 1 min and persisted in the plasma membrane
even at 27 min after receptor engagement.
 
Vav Colocalization with Fc
 
e
 
RI Is Dependent on an Intact
SH2 Domain.
 
We previously reported the specific coim-
munoprecipitation of Fc
 
e
 
RI with Vav in response to
Fc
 
e
 
RI engagement (10). We revisited this issue to explore
whether the observed aggregates of Vav represent the frac-
tion of Vav that might colocalize with Fc
 
e
 
RI. Fc
 
e
 
RI was
evenly distributed in unstimulated control (GFP) and Vav
(Vav-GFP) transfected cells (Fig. 2 A, Anti-
 
b
 
). After Fc
 
e
 
RI
engagement, microaggregates of Fc
 
e
 
RI were formed at the
plasma membrane. This is in agreement with earlier reports
of Fc
 
e
 
RI clustering after stimulation, as visualized with
FITC- or PE-labeled IgE (37–39). In adherent cells, these
Fc
 
e
 
RI microaggregates appeared to focalize to the cell–cell
contact points after Fc
 
e
 
RI engagement (Fig. 2 A). Vav and
Fc
 
e
 
RI aggregates showed an identical distribution, with a
significant fraction of Fc
 
e
 
RI codistributing with Vav in the
stimulated adherent (Fig. 2 A) and in nonadherent cells
(data not shown). Colocalization of a considerable fraction
of Fc
 
e
 
RI aggregates (
 
.
 
30%) with plasma membrane–local-
ized Vav aggregates was observed (Fig. 2 A, Overlay).
We previously found that Vav did not directly interact
with the Fc
 
e
 
RI
 
g
 
 ITAMs. Nevertheless, as Vav is known to
be phosphorylated by and to interact with Syk (17, 29, 30),
we investigated which structural domain(s) of Vav might
be important for its colocalization with Fc
 
e
 
RI. Fig. 2 B
shows that deletion of the CH, DH, and PH domains had
little effect on Vav redistribution and colocalization with
Fc
 
e
 
RI. Only the SH2 domain was found to be important
for redistribution of Vav to the plasma membrane and for
its colocalization with Fc
 
e
 
RI. Deletion of the SH2 domain
(data not shown) or mutation of R694K in the SH2 do-
main of Vav completely ablated the plasma membrane re-
distribution of Vav and thus the colocalization with Fc
 
e
 
RI
(Fig. 2 B). As shown in Fig. 2 C, a fluorescence intensity
profile of Fc
 
e
 
RI-stimulated cells expressing Vav-GFP showed
almost complete fluorescence overlap with Fc
 
e
 
RI com-
pared with cells expressing the R694K mutation of Vav. In
addition, the deletion or mutation of the Vav SH2 domain
also resulted in the loss of Vav tyrosine phosphorylation
(Fig. 2 D) while no significant effect on the phosphoryla-
tion of the CH, DH, or PH domain–deleted constructs was
observed (data not shown). Thus, one might conclude that
plasma membrane localization is required for Vav phosphor-
ylation. Alternatively, the Vav SH2 domain–mediated in-
teraction with Syk or ZAP-70 (17, 40) may be required for
Vav phosphorylation, or both possibilities may contribute
to Vav phosphorylation.
 
The SH2 Domain of Vav Contributes to JNK1 Activation.
 
Kinetic analysis of JNK1 activation in RBL cells revealed
that maximal enzymatic activity was at 8 min after Fc
 
e
 
RI
engagement (our unpublished results). Fc
 
e
 
RI engagement
(8 min) of cells overexpressing wild-type Vav enhanced the 
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activation of JNK1 (Fig. 2 E). We investigated the impor-
tance of the SH2 domain for Vav function by studying
whether the Vav mutant (R694K) was capable of enhanc-
ing JNK1 activation. Mutant Vav (R694K) did not en-
hance the JNK1 activation, unlike the wild-type Vav (Fig.
2 E). In addition, more prolonged (16 min) Ag stimulation
of cells expressing Vav (R694K) did not provide any en-
hancement of JNK1 activity (data not shown). The JNK1
response for the mutant Vav (R694K) was similar to that
observed for the control GFP transfectant, suggesting that
this mutation did not exhibit a dominant negative pheno-
type. Additionally, as we reported elsewhere (13), the dele-
tion of the Vav DH domain also resulted in reduced JNK1
activation and mimicked the expression of an inactive
Rac1 (N17). Deletion of the CH or PH domains showed
no or little effect, respectively, on JNK1 activation. Thus,
because ablation of the GEF activity (DH
 
2
 
) of a plasma
membrane localized Vav (Fig. 2 B) or inhibition of redistri-
Figure 1. Distribution of Vav in RBL-2H3 mast cells. (A) Cells
were transfected with GFP, Vav-GFP, or analyzed for endogenous
Vav. Nontransfected or 4 h posttransfected cells were fixed (nontrans-
fected cells were immunostained for endogenous Vav) and examined
by confocal microscopy. A fluorescence intensity (arbitrary units) pro-
file shows the cytosolic localization of Vav, Vav-GFP, and the uni-
form distribution of GFP. (B) 4 h posttransfected GFP or Vav-GFP
expressing cells sensitized with IgE were stimulated or not (0 ng) with
3, 30 , 90, or 300 ng of Ag (DNP-HSA) for 3 min at 378C. Cells were
fixed and examined by confocal laser microscopy. Bars, 10 mm. 
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Figure 2. Vav phosphorylation, JNK1 activation, and FceRI colocalization are dependent on the Vav SH2 domain. (A) Vav colocalizes with FceRI.
RBL-2H3 cells transfected with GFP or Vav-GFP were sensitized with IgE and stimulated with 30 ng of Ag (Ag1) or not (Ag2) for 3 min. Cells were
fixed, permeabilized, and incubated with mouse anti-FceRI b chain followed by Cy-5–conjugated goat anti–mouse. Overlay shows colocalization (yel-
low) where the green and red fluorescence overlap. (B) Mutants of Vav-GFP were analyzed for distribution after Ag stimulation as above. R694K, a Vav
SH2 domain mutant, a PH domain–deleted mutant (2PH), a DH domain–deleted mutant (2DH), and a CH domain–deleted mutant (2CH) were an-
alyzed as above for plasma membrane localization and colocalization with FceRI. (C) The SH2 domain of Vav is required for colocalization with FceRI.
Fluorescence pixel intensity (arbitrary units) profile of FceRI (red line) and Vav (green line) from the plasma membrane of FceRI-stimulated cells trans-
fected with Vav-GFP or Vav-GFP (R694K). (D) Tyrosine phosphorylation of Vav requires its SH2 domain. RBL-2H3 cells were transfected with Vav-
GFP, Vav-GFP (R694K), or Vav-GFP (2SH2 domain). 4 h posttransfection cells were stimulated with 300 ng/ml of Ag for 3 min, lysed, and incubated
with anti-GFP. SDS-PAGE–resolved proteins were transferred for immunoblotting (IB). Blots were first probed with antiphosphotyrosine (Anti-PY),
then stripped and reprobed with anti-Vav. (E) An intact Vav SH2 domain is needed for JNK1 activation. RBL-2H3 cells were transfected with GFP,
Vav-GFP, or Vav-GFP (R694K). Cells were stimulated (Ag1) or not (Ag2) for 8 min as in D, and incubated with anti-JNK1. Immunoblots (IB) were
first probed with antiphospho-JNK1, then stripped and reprobed with anti-JNK1. Quantitation of immunoblots was by densitometry. Fold induction is
the mean of three experiments where values obtained were normalized to the immunoprecipitated protein. SD were ,10%.52 Vav Localizes to the Plasma Membrane
bution of wild-type Vav to the plasma membrane resulted
in a loss of enhanced JNK activity, we conclude that the
movement of Vav to the plasma membrane is important to
its role in JNK1 activation.
Syk Activity Is Required for Vav Redistribution. Inhibition of
Syk activity or a deficiency of Syk in mast cells results in
the loss of Vav phosphorylation (30, 41). To assess if Vav
redistribution was dependent on Syk activity or on the
presence of Syk, we used several approaches. Vav was over-
expressed in the TB1A2 cells, a Syk2 RBL-2H3 cell line
(30). In the absence or presence of FceRI engagement, Vav
failed to redistribute to the plasma membrane and form ag-
gregates (Fig. 3 A). Furthermore, analogous to the muta-
tion of the Vav SH2 domain, the endogenous and overex-
pressed Vav was not phosphorylated in these cells (Fig. 3 B,
and data not shown). Cotransfection of Syk and Vav in the
TB1A2 cells led to the reconstitution of plasma mem-
brane–localized Vav, its tyrosine phosphorylation, and its
colocalization with FceRI after the latter’s engagement
(Fig. 3, A and B). As summarized in Table I, Vav aggregates
were also observed after FceRI engagement in a TB1A2-
derived clone stably reconstituted with Syk (clone 3A1). In
contrast, the TB1A2-derived clone reconstituted with a
catalytically inactive Syk (clone 3BA12) or RBL cells pre-
treated with piceatannol, a Syk-selective inhibitor, failed to
show Vav redistribution (Table I), clearly demonstrating the
requirement for Syk activity in the tyrosine phosphorylation
of Vav and its redistribution to the plasma membrane.
We also found that Syk and Vav synergized in the acti-
vation of JNK1 in Syk-deficient cells. Expression of Vav
alone in these cells, followed by FceRI engagement, caused
a 2.2-fold enhancement in JNK1 activation compared with
the control nonstimulated GFP transfectant (Fig. 3 C). Ex-
pression of Syk alone also caused a 2.3-fold enhancement
in JNK1 activity. However, a 3.6-fold increase in JNK1 ac-
tivation was seen when Vav was coexpressed with Syk. As
shown below, the activation of JNK1 required the plasma
membrane localization of Vav.
We investigated whether Syk mediates the interaction of
Vav with the plasma membrane. The following evidence
suggested that Vav aggregate formation is not directly me-
diated by Vav interaction with Syk. First, we did not detect
colocalization of Vav with Syk under conditions, described
previously (39), where Syk is maximally localized to the
Figure 3. Vav phosphorylation, membrane localization, and JNK1 activation depends on Syk activity. (A) Plasma membrane localization of Vav re-
quires Syk activity. Syk-deficient cells (2Syk) were transfected with Vav-GFP (2Syk/1Vav-GFP) or with both Vav-GFP and Syk (1Syk/1Vav-GFP).
Transfected cells were stimulated for 3 min with 30 ng of Ag (1Ag). Fixed and permeabilized cells were incubated with mouse antibody to FceRI b chain
followed by Cy-5–conjugated goat anti–mouse. (B) Vav tyrosine phosphorylation requires Syk. Syk-deficient cells were transfected with Vav-GFP or
with both Vav-GFP and Syk. FceRI-stimulated (Ag1) cells were lysed and incubated with anti-GFP. Proteins were resolved and transferred for immu-
noblots (IB) and probed with antiphosphotyrosine (Anti-PY), then stripped and reprobed with anti-Vav. (C) Syk and Vav synergize to activate JNK1.
Syk-deficient cells were transfected with either GFP, Syk, Vav-GFP, or both Vav-GFP and Syk. Transfected cells were stimulated (Ag1) or not (Ag2)
with 300 ng/ml of Ag for 8 min, lysed, and incubated with antibody to JNK1. Resolved proteins were first immunoblotted with anti-phosphoJNK1,
then stripped and reprobed with anti-JNK1. Quantitation of immunoblots (IB) was by densitometry. Fold induction is the mean of two experiments
where values obtained were normalized to the immunoprecipitated protein. SD were ,7%.53 Arudchandran et al.
plasma membrane (data not shown). Second, other adaptor
proteins that could facilitate Vav interaction with the
plasma membrane were localized with Vav aggregates (see
Fig. 4, D and E, and Fig. 5 A). Third, preliminary experi-
ments in FceRI- and Lyn-transfected Chinese hamster
ovary (CHO) cells (42) showed no redistribution of trans-
fected Vav to the plasma membrane under conditions
where Syk was membrane localized and both Syk and Vav
were tyrosine phosphorylated (data not shown). Although
we cannot formally exclude a plasma membrane–localized
interaction of Syk and Vav, the preponderance of evidence
suggests a different mechanism for Vav plasma membrane
association.
Vav, LAT, Rac1, and FceRI Are Found in GEMs. Bio-
chemical studies demonstrated the constitutive association
of Vav with Grb2 (10, 21, 22) and the receptor-dependent
association of Vav with SLP-76 (19, 43, 44) and LAT (45).
LAT is a palmitoylated protein that partitions to GEMs and
can form a complex with SLP-76 and Vav (9, 46). To es-
tablish a link of communication, it was possible that Vav
and FceRI might be found in GEMs after FceRI engage-
ment. Because the SH2 domain of Vav is critical for plasma
membrane localization, we reasoned that the SH3-SH2-
SH3 domains of Vav (Vav-C), which were previously de-
scribed to inhibit Vav activity (19), might compete with
endogenous Vav for plasma membrane localization. To test
this hypothesis, we investigated whether Vav-C would lo-
calize to the plasma membrane by expressing both Vav-C
and Vav-C (R694K) tagged with GFP and subsequently
engaging the FceRI. Vav-C was redistributed to the plasma
membrane, whereas the Vav-C (R694K) mutant failed to
membrane localize (Fig. 4 A). The expression of GFP,
Vav-C, or Vav-C (R694K) was found to be similar (Fig. 4
B). In addition, Vav-C was tyrosine phosphorylated as de-
scribed (19), whereas Vav-C (R694K) was only weakly
phosphorylated (data not shown). This suggested that Vav-C
might act as a competitive inhibitor of Vav phosphoryla-
tion, and led us to explore its effect on the phosphorylation
of wild-type Vav. Fig. 4 C shows that Vav-C inhibited the
tyrosine phosphorylation and association of Vav with Syk,
whereas Vav-C (R694K) did not. In addition, although in
the experiment shown there is a minor effect on Syk phos-
phorylation, multiple experiments suggested that Vav-C
expression had no effect on Syk phosphorylation before or
after FceRI engagement. Therefore, Vav-C competes with
Vav as a substrate for Syk and can localize to the plasma
membrane as a competitor for endogenous Vav.
We established that immunoprecipitation of endogenous
Vav or LAT resulted in the coimmunoprecipitation of en-
dogenous LAT, Grb2, SLP-76, or Vav (Fig. 4 D). We used
the expression of Vav-C to analyze whether the competitor
had any effect on formation of a multiprotein complex of
Vav with the SLP-76 and LAT. SLP-76 was immunopre-
cipitated from FceRI-stimulated or -nonstimulated cells
that were transiently transfected with Vav tagged with GFP
(to enhance the formation of a complex with SLP-76) in
the presence of the Vav-C inhibitor also tagged with GFP,
or of GFP alone. SLP-76 immunoprecipitates from the
stimulated cells that were expressing Vav-C showed marked
inhibition of Vav coimmunoprecipitation with SLP-76
(Fig. 4 E). Moreover, an inhibition of LAT association
with SLP-76 was also observed, although this was not as
dramatic as the inhibition of Vav and SLP-76 interaction
(Fig. 4 E). The association of Grb2 with SLP-76 was not
inhibited (Fig. 4 E). As determined by immunoprecipitat-
ing each individual protein, no effect on the tyrosine phos-
phorylation of Syk, SLP-76, or LAT (Fig. 4, C, E, and F)
was observed by expression of Vav-C or the controls, Vav-C
(R694K) and GFP. Therefore, Vav-C specifically inhib-
its Vav phosphorylation and its association with SLP-76
and LAT.
In RBL-2H3 cells, a significant fraction (as much as 50%)
of the FceRI can be found in GEMs after extensive aggre-
gation of this receptor (6). Given that LAT is also found in
these domains (9), we now asked whether Vav might also
be recruited to these membrane domains in response to
FceRI engagement. Furthermore, if the LAT/SLP-76/Vav
complex formation takes place in the GEMs, we should ef-
fectively compete the recruitment of Vav in the GEMs by
overexpression of Vav-C. Fig. 5 A shows that Vav and FceRI
are recruited in the LAT-containing GEMs (fractions 4–6)
after FceRI engagement. FceRI recruitment to GEMs was
primarily monitored by the irreversible binding of radiola-
beled IgE (47; see graph, Fig. 5 A) and ranged from 15 to
50% with a mean of 20%. However, we could also detect
the presence of phosphorylated FceRI  b chain and the
GEM-localized Lyn (6), but not paxillin (a GEM-excluded
protein [48]), when tested by immunoblotting (data not
shown, and Fig. 5 A). The presence of Vav in the GEMs
Table I. Vav Plasma Membrane Localization Is Syk Dependent
Cell line
(Transfectant or treatment)‡
Vav plasma membrane
localization*
Ag§: 21
RBL-2H3 2 1111
RBL-2H3
(Piceatannol) 22
TB1A2
(Syk2 cells) 22
TB1A2
(Syk1, transient transfection) 2 111
3A1 (TB1A2 derived)
(Stable wild-type Syk) 21 1
3BA12 (TB1A2 derived)
(Stable catalytically inactive Syk) 22
*Localization of Vav was determined by counting the number of
plasma membrane–localized Vav-GFP aggregates in 100 cells by confo-
cal laser microscopy. Aggregate number relative to RBL-2H3 is shown
as a plus sign (1).
‡Syk-deficient or reconstituted RBL-2H3 variants were used as indi-
cated. Parental RBL-2H3 were used for the piceatannol experiments.
§Stimulation of cells was with 30 ng of Ag (DNP-HSA).54 Vav Localizes to the Plasma Membrane
was effectively reduced by the overexpression of Vav-C
but not by the overexpression of the control Vav-C
(R694K). In five experiments, inhibition of Vav localiza-
tion to GEMs by Vav-C ranged from 35 to 100%. Both
exogenously and endogenously expressed Vav were tyro-
sine phosphorylated and localized to the GEMs, and the
localization was inhibited by Vav-C expression (Fig. 5 A).
No inhibition was observed by expression of Vav-C
(R694K) (Fig. 5 A). In addition, we also found that Rac1,
the target of Vav GEF activity, was constitutively present
Figure 4. Vav-C inhibits Vav phos-
phorylation and association with but not
phosphorylation of Syk, SLP-76, and
LAT. (A) Vav-C (SH3-SH2-SH3) is
membrane localized upon FceRI en-
gagement. RBL-2H3 cells were trans-
fected with Vav-C-GFP or an SH2 do-
main–mutated Vav-C (R694K)-GFP.
Cells were stimulated with 30 ng/ml of
Ag for 3 min (1Ag) or left untreated
(2Ag) and examined by confocal laser
microscopy. (B) Expression levels of
GFP alone, Vav-C, or Vav-C (R694K)
tagged with GFP. Cells transfected as in
A were lysed, and 5 3 104 cell equiva-
lents per lane of protein were resolved
by SDS-PAGE and transferred for im-
munoblotting (IB). For immunoprecipi-
tation experiments, 1.0–2.0 3 107 cells
were used. Expression levels were determined by probing with an antibody to GFP (shown) or in some cases with a mouse mAb to Vav. (C) Vav-C in-
hibits phosphorylation of Vav and its association with Syk but not Syk phosphorylation. RBL-2H3 cells transfected with Vav, Vav-C, and Syk or Vav,
Vav-C (R694K), and Syk were stimulated as in the legend to Fig. 2 D, lysed, and incubated with antibody to Syk. Recovered proteins were immuno-
blotted (IB) with antiphosphotyrosine (Anti-PY), then stripped and reprobed sequentially with anti-Vav and anti-Syk. (D) Nontransfected RBL-2H3 cells
were stimulated (Ag1) or not (Ag2) as in the legend to Fig. 2 D. Cells were lysed as described in Materials and Methods, and LAT or Vav was immu-
noprecipitated. Proteins were resolved and immunoblotted with antibody to LAT, SLP-76, and Vav. (E) Vav-C inhibits the association of Vav and LAT
with SLP-76 without affecting the SLP-76 phosphorylation. RBL-2H3 cells were transfected with Vav and GFP or Vav and Vav-C-GFP. Cells were
stimulated (Ag1) or not (Ag2) as in the legend to Fig. 2 D, then lysed and incubated with antibody to SLP-76. Immunoblots were first probed with an-
tiphosphotyrosine (Anti-PY), then stripped and reprobed with anti–SLP-76, anti-Vav, anti-LAT, and anti-Grb2. (F) Vav-C has no effect on the tyrosine
phosphorylation of LAT. Experiments were done as in E, but cell lysates were incubated with antibody to LAT (Anti-LAT). Immunoblots were probed
with antiphosphotyrosine and subsequently with anti-LAT.55 Arudchandran et al.
in GEMs and its presence in GEMs was slightly increased
by FceRI engagement (Fig. 5 A). This is consistent with a
recent study (49) demonstrating that Rac1 is constitutively
present in caveolae and is further recruited to these mem-
brane domains in response to platelet-derived growth fac-
tor. Thus, engagement of FceRI actively recruits phosphor-
ylated Vav and FceRI into LAT- and Rac1-containing
GEMs, suggesting that the presence of Vav in these do-
mains may be functionally important.
Vav Activity Is Required for JNK1 Activation. To address
the functional importance of Vav, we tested whether the
expression of Vav-C would have an effect on endogenous
Vav activity and explored the possible correlation with the
formation of a Vav-containing GEM-residing complex.
Because a Vav-dependent activation of JNK1, which mim-
ics Rac1 activation of JNK1, had been demonstrated (13,
31, 50), we assayed for the activation of JNK1 in cells ex-
pressing Vav-C. We chose to look at JNK1 activity, rather
than its phosphorylation, to obtain a more direct quantita-
tive measure of any effect. As shown in Fig. 5 B, expression
of Vav-C inhibited the tyrosine phosphorylation of endog-
enous Vav and decreased the FceRI-induced JNK1 activa-
tion by 81 6 17%. Some reduction of the basal levels of
JNK1 activity in these cells was also observed. No effect was
observed by expression of either GFP or Vav-C (R694K) as
controls. Thus, the expression of Vav-C, which inhibits
Vav phosphorylation and movement to GEMs, also results
in inhibition of FceRI-mediated JNK1 activation (Fig. 5 B)
in the absence of an effect on Syk activity or on the phos-
phorylation of SLP-76 and LAT (Fig. 4, C, E, and F). We
previously demonstrated (13) that the constitutively active
Rac1 (V12) and the inactive Rac1 (N17) (which function
at the plasma membrane [12, 49]) mimic or inhibit, respec-
tively, Vav-induced JNK1 activation. Thus, collectively,
Figure 5. LAT, Rac 1, FceRI, and Vav are constitutively
present or recruited to GEMs: Vav localization to GEMs and
JNK1 activation are inhibited by Vav-C expression. (A) RBL-
2H3 cells were transfected with Vav-GFP and Vav-C or Vav-GFP
and Vav-C (R694K). Cells were sensitized with 125I-IgE and stim-
ulated (Ag1) or not (Ag2) as in the legend to Fig. 2 D. GEMs
were isolated as described (reference 35), and Vav or LAT was im-
munoprecipitated from pooled fractions or proteins concentrated
by TCA precipitation. Proteins were immunoblotted with anti-
Vav, anti-LAT, anti-Rac1, or anti-Lyn. Numbers indicate pooled
fractions (GEMs are found in fractions 4–6). The equivalent frac-
tions from nonstimulated (Ag2) and FceRI-stimulated (Ag1) cells are shown next to each other. PNS, postnuclear supernatant. Lyn was used as a posi-
tive control for the GEM fraction (reference 65), whereas the absence of paxillin in GEMs was a negative control (reference 48). FceRI distribution be-
fore and after stimulation is shown as a percentage of the total 125I-IgE recovered in the pooled fractions. (B) Vav-C inhibits the FceRI-mediated
activation of endogenous JNK1. RBL-2H3 cells were transfected with GFP or Vav-C-GFP. Cells were stimulated as in the legend to Fig. 2 E (Ag1) or
not (Ag2). Cells were lysed, and endogenous JNK1 and Vav were immunoprecipitated. Vav blots were first probed with antiphosphotyrosine (Anti-PY)
and then with anti-Vav. For direct quantitation of activity, in-gel kinase assays were performed with JNK1 immunoprecipitates as described (reference
36). Quantitation was by Molecular Storm® imaging (Molecular Dynamics). One representative of four experiments using either GFP or Vav-C
(R694K)-GFP as negative controls is shown. No difference was observed with either negative control.56 Vav Localizes to the Plasma Membrane
our results suggest that phosphorylation of Vav and/or for-
mation of a Vav-containing plasma membrane–localized
multiprotein complex may be required for the Vav-depen-
dent activation of JNK1 after FceRI engagement.
Discussion
This study demonstrates that Vav moves to the plasma
membrane upon FceRI engagement (Fig. 6). In addition,
we found that most of the membrane-localized Vav and a
portion of the FceRI partition to LAT- and Rac1-contain-
ing GEMs (Fig. 5 A), suggesting that these specialized mem-
brane domains represent sites where receptors engage down-
stream effectors. Because Vav forms a complex with SLP-76
and LAT (9, 19, 44, 45), our findings promote the view
that Vav functions as part of a multiprotein signaling com-
plex that is engaged by the FceRI in the GEMs (Fig. 6).
The movement of Vav to the plasma membrane is de-
pendent on Syk activity and the SH2 domain of Vav. Inter-
estingly, we did not observe a loss in plasma membrane lo-
calization by deletion of the PH domain of Vav (Fig. 2 B),
a domain thought to be important for membrane targeting
and Vav function (14, 51). Thus, only the SH2 domain was
found to mediate association with the plasma membrane
components. The importance of this domain to the activa-
tion of Vav is underscored by the inability to phosphorylate
the Vav (R694K) mutant in Syk-containing cells (Fig. 2 D)
and the inhibition of Vav phosphorylation by Vav-C,
which also inhibits Vav binding to Syk in the absence of an
effect on Syk phosphorylation (Fig. 4 C). Mutations of both
Y342 and Y346 of rat Syk or the equivalent tyrosines on
ZAP-70 have been demonstrated to inhibit Vav interaction
(17, 18). These mutations also inhibit the tyrosine phos-
phorylation of Vav (Yamashita, T., personal communica-
tion). Thus, the use of the above Syk mutant would not allow
us to distinguish whether Syk activity or Syk interaction is
necessary for Vav redistribution. At present, our data sug-
gest that the association of Vav with the plasma membrane
is not mediated by Syk. This conclusion is best supported
by our preliminary results in FceRI-transfected CHO cells
(42) in which phosphorylation of receptor Syk and Vav did
not result in Vav plasma membrane localization (under con-
ditions where Syk was membrane localized). These results
also suggest that Vav phosphorylation is not the sole require-
ment for plasma membrane localization. However, we can-
not formally exclude the possibility that Syk might mediate
some association of Vav with the plasma membrane.
Vav also interacts with adaptor proteins like SLP-76 that
mediate binding to plasma membrane–localized scaffolding
proteins like LAT (46) and thus could provide plasma
membrane localization of Vav. Because a significant frac-
tion of phosphorylated LAT is localized to GEMs (9; and
Fig. 5 A), communication between the Vav-containing
molecular complex and FceRI may likely occur in GEMs.
Preliminary support for this hypothesis is provided by the
similar kinetics of FceRI and Vav localization to GEMs (6,
52; and this study) and also by the observation that coex-
pression of Vav-C, which inhibits FceRI-mediated JNK1
activation (Fig. 5 B), also effectively inhibited the presence
of endogenous and exogenous Vav in GEMs (Fig. 5 A). In
addition, the previous finding (13) that a DH domain–
deleted Vav is incapable of activating JNK1 although it lo-
Figure 6. Model of FceRI communication with Vav.
FceRI engagement results in Lyn phosphorylation of the
ITAMs of the receptors and recruitment of receptors
into GEMs (1). Which step occurs first is presently un-
clear. Syk is recruited to the phosphorylated ITAMs of
FceRI and is activated (2). Syk may target Vav for phos-
phorylation in the membrane or cytosol. Our data show
the presence of phosphorylated Vav in both the cytosol
and membrane, suggesting the possibility that phosphor-
ylation may take place in the cytosol before membrane
localization (3). Phosphorylated Vav can associate with
the adaptor protein, SLP-76, which can mediate Vav
movement to the GEMs because of SLP-76 binding to
the scaffold protein, LAT, which is found in GEMs. Re-
cruitment of Vav into these domains allows Vav to tar-
get Rac1 and activate it (4). Full activation of JNK1 via
the FceRI requires Vav activity.57 Arudchandran et al.
calizes to the plasma membrane (Fig. 2B) underscores the
importance of functional Vav in the plasma membrane.
Thus, collectively, the findings promote the view that re-
cruitment of Vav to GEMs may be an important step that
couples the FceRI (6) to a macromolecular complex that
regulates JNK1 activation (2, 53–55).
Although not all of the cellular Vav moves to the plasma
membrane, of the fraction localized in the plasma mem-
brane almost all could be found to colocalize with the
FceRI (see Fig. 2, A and C). In contrast, z30% of recep-
tors were found to colocalize with Vav. This may reflect
the possibility that only activated receptors, or alternatively
only receptors that become active, can associate with Vav.
Our data are consistent with a possible site of communica-
tion for FceRI and Vav being in GEMs, because the num-
bers obtained for colocalization correspond nicely with the
fraction of FceRI found in our study to be recruited to
GEMs (z20%). In addition, these numbers are also consis-
tent with the best estimates of the number of FceRI mole-
cules (25%) that have the potential to associate with the acti-
vating Lyn kinase in RBL-2H3 cells (56). Thus, our findings
support the notion that the fraction of FceRI found in
GEMs is active (6) and can link to downstream effectors
like Vav. Notably, although phosphorylation of the FceRI
is not required for GEM localization (6), we found that re-
ceptors in the GEMs showed at least a 13-fold higher level
of FceRI b chain phosphorylation compared with the re-
maining receptors after normalization for protein content
(data not shown). This is consistent with the studies of
Field and colleagues (6) and suggests that the GEMs may
function both as a site of receptor phosphorylation (6) and a
site where receptors engage other signaling molecules (8).
Among the numerous proteins localized to GEMs, LAT
has been clearly demonstrated to play an important func-
tional role in TCR signaling (45, 46). A recent study dem-
onstrated that the costimulatory effects of CD28 on TCR-
dependent activation are mediated by the CD28-dependent
clustering of GEMs to the TCR (57). Thus, sustained T
cell activation and/or sensitivity of TCR engagement is
seemingly dependent on the coclustering of the TCR/CD28
in GEMs and is likely to be dependent on communication
with LAT (45, 46, 57). In mast cells, a phosphoprotein of
the approximate molecular mass of LAT was first described
by Turner and colleagues as an FceRI-activated link to
Grb2-Sos (58). This protein was recently identified in
RBL-2H3 mast cells as LAT (46). This scaffold protein is
important in assembling a macromolecular signaling com-
plex that includes at least phospholipase Cg1, SLP-76, Vav,
Grb2, and Cbl (45, 46). We now demonstrate that in mast
cells LAT, Rac1, and Vav are found in the GEMs. The
FceRI is also found in GEMs (6), and specific inhibition of
Vav phosphorylation, which also inhibits its localization to
GEMs, has a significant downregulatory effect on FceRI-
mediated JNK1 activation. Although we cannot formally
exclude the possibility that another fraction (other than the
plasma membrane–localized fraction) of Vav is responsible
for JNK1 activation, it is likely that a mechanism similar to
that required for activation of Ras on the plasma mem-
brane (59) may also function to activate Rac. In the present
model (Fig. 6), activated Vav (a Rac1 GEF) is sequestered
on the plasma membrane by the LAT–SLP-76 complex
where it activates Rac1.
Recent studies (55, 60, 61) on T cells derived from Vav-
null mice reported differences in mitogen-activated protein
kinase (MAPK) activation. Costello and colleagues (61)
demonstrated that in T cells from these mice, extracellular
signal–regulated kinase (ERK) activation was impaired. In
contrast, the studies of Fischer et al. (60) and Holsinger et al.
(55) found no effect on ERK or JNK activation. However,
we (13) and others (31, 50) have observed Vav-mediated
JNK activation in various cell types. The apparent discrep-
ancy may be explained by cell type differences (i.e., mast
cells versus T cells), redundancy of signaling pathways, or as
proposed by Costello et al. (61), differences in the knock-
out targeting strategy that could result in low levels of Vav
expression. Nevertheless, because we demonstrate an effect
on JNK1 activation by the deletion of the Vav SH2 do-
main and by expression of Vav-C, and found that Syk and
Vav synergize to enhance JNK1 activation, we propose
that Vav significantly contributes to FceRI-mediated JNK1
activation. Moreover, this hypothesis is also supported by
our recent findings that the inactive mutants Rac1 (N17)
or JNK (APF) inhibit Vav-dependent JNK1 activation in
the RBL-2H3 mast cell line (13).
A recent study (43) demonstrated that mutation of
SLP-76 (Y112F, Y128F, Y145F) or mutation of the Vav
SH2 domain abrogated both TCR-dependent cytoskeletal
rearrangement and p21-activated kinase (PAK) activation.
This is consistent with our findings that the SH2 domain of
Vav is important for JNK activation, since PAK functions
upstream of JNK activation in mast cells (62) but down-
stream of the Vav target, Rac1 (13, 50). We also observed
that the expression of Vav-C, which localizes to the plasma
membrane upon FceRI stimulation and inhibits Vav phos-
phorylation (Figs. 4 A and 5 B), resulted in the inhibition
of Vav association with SLP-76 and partial inhibition of
LAT interaction with SLP-76 without affecting the tyro-
sine phosphorylation of LAT and SLP-76 (Fig. 4, E and F).
Since Vav, LAT, and SLP-76 can participate in a complex,
and along with Rac1, are localized in GEMs, we propose
that this multiprotein signaling complex is important to Vav
function, including its ability to activate JNK1. In SLP-
76–deficient T cells (63), phosphorylation of the calcium
response modulator, phospholipase Cg1, was decreased;
thus, it is also possible that a partial loss of the SLP-76 and
LAT interactions in the absence of Vav may explain the
defective calcium response of Vav-null cells (64). This pos-
sibility is currently being explored. The model proposed in
Fig. 6 provides a possible mechanism for Vav contribution
to cytoskeleton rearrangement, calcium signals, and kinase
activation. By complexing with a LAT-organized multi-
protein signaling complex (45), Vav activity and protein in-
teractions may contribute to activation of Rac (11, 13, 50),
Ras (10, 15, 45), and calcium signals (45, 55, 60, 64), thus
participating in cytoskeletal rearrangement, MAPK activa-
tion, and gene expression (13, 19).58 Vav Localizes to the Plasma Membrane
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